JP2004149468A - Skin preparation composition for external use - Google Patents

Skin preparation composition for external use Download PDF

Info

Publication number
JP2004149468A
JP2004149468A JP2002317621A JP2002317621A JP2004149468A JP 2004149468 A JP2004149468 A JP 2004149468A JP 2002317621 A JP2002317621 A JP 2002317621A JP 2002317621 A JP2002317621 A JP 2002317621A JP 2004149468 A JP2004149468 A JP 2004149468A
Authority
JP
Japan
Prior art keywords
water
ascorbic acid
phosphate
preparation composition
freeze
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2002317621A
Other languages
Japanese (ja)
Other versions
JP4377123B2 (en
Inventor
Hiroshi Yamaguchi
浩史 山口
Minoru Shirono
実 白野
Masato Kono
正登 河野
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Nikko Pharmaceutical Co Ltd
Original Assignee
Nikko Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Nikko Pharmaceutical Co Ltd filed Critical Nikko Pharmaceutical Co Ltd
Priority to JP2002317621A priority Critical patent/JP4377123B2/en
Publication of JP2004149468A publication Critical patent/JP2004149468A/en
Application granted granted Critical
Publication of JP4377123B2 publication Critical patent/JP4377123B2/en
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Abstract

<P>PROBLEM TO BE SOLVED: To provide a skin preparation composition for external use excellent in formability, solubility, high-temperature stability and impact resistance as well as solving the problem that an L-ascorbic acid-2-phosphate is unstable in the presence of water. <P>SOLUTION: The skin preparation composition for external use is obtained by lyophilizing an aqueous solution blended with (a) an L-ascorbic acid-2-phosphate, (b) a low-hygroscopic oligosaccharide, (c) a sugar alcohol and (d) a water-soluble polymer. This akin preparation composition is to be used after being dissolved in water or a skin lotion or the like. <P>COPYRIGHT: (C)2004,JPO

Description

【0001】
【発明の属する技術分野】
本発明は、水との共存下で不安定な水溶性アスコルビン酸誘導体であるL−アスコルビン酸−2−リン酸塩を安定に保つことのできる皮膚外用剤組成物に関する。
【0002】
【従来の技術】
L−アスコルビン酸−2−リン酸塩は、メラニン生成抑制、抗酸化性、ラジカルスカベンジ能、コラーゲン合成の促進等の高い有用性が認められることから、肌のしみやそばかすの治療や予防、こじわの予防、肌に潤いを与える等の様々な目的で各種皮膚外用剤組成物に配合されている。
【0003】
L−アスコルビン酸−2−リン酸塩は水との共存下で酸化、pHの変化、微生物等の影響を受けやすく、その結果、L−アスコルビン酸−2−リン酸塩が分解する等の問題が発生し、それにより系の外観が黄変化したり、変臭を伴ったりするといった問題が生じてしまい、使用時まで系の状態を一定に保ち、L−アスコルビン酸−2−リン酸塩を安定に保つことは困難であるのが現状であった。
【0004】
このような問題を解決するために、従来から金属封鎖剤や防腐剤、pH調整剤等の安定剤を配合して、L−アスコルビン酸−2−リン酸塩を安定に保つ工夫が行われてきた。
【0005】
しかしながら、上記の解決方法では、特に変色、変臭という点では満足のいくものが得られず、また、安定に保つためには安定剤の配合量を大幅に増やす必要があることから、肌への負担が大きく、使用感も劣るものとなってしまい、改善が求められていた。
【0006】
一方で、安定剤の配合を増やすことなく改善できる方法として、L−アスコルビン酸−2−リン酸塩を凍結乾燥するといった方法が挙げられる(特開平10−130124)。しかしながら、L−アスコルビン酸−2−リン酸塩は非常に吸湿性が強いために、凍結乾燥後、空気中の水分を含んでしまい、変色、変臭や溶解性の悪化を招くことがしばしばあること、高い吸湿性ゆえ、比較的高い配合量での凍結乾燥が製造上困難であるケースがあった。さらに、これらの現象を防ぐために糖アルコールを添加する方法が用いられるが、糖アルコール自体にも吸湿性を有するために、L−アスコルビン酸−2−リン酸塩を凍結乾燥する上では十分なものではなかった。
【0007】
また、低吸湿性のオリゴ糖のみを用い凍結乾燥を行うと(特開2002−000248)、凍結乾燥物の収縮が激しく、脆く割れ・カケが起りやすいという欠点があり、商品価値を大きく損ねることがあった。
【0008】
【発明が解決しようとする課題】
本発明は、水溶性アスコルビン酸誘導体であるL−アスコルビン酸−2−リン酸塩が水との共存下で不安定であるという課題を解決するとともに、成形性、保形性に優れ、適度な固さを保ち輸送途上で割れ・カケ等が起こりにくく、吸湿等の影響によるL−アスコルビン酸−2−リン酸塩の劣化・収縮がなく、安定性に優れ、使用時に容易に水等で溶解することができる皮膚外用剤組成物を提供することを目的とする。
【0009】
【課題を解決するための手段】
本発明者等は、皮膚外用剤組成物において、上記課題を解決するため鋭意研究を行った結果、水との共存下で不安定な水溶性アスコルビン酸誘導体であるL−アスコルビン酸−2−リン酸塩を、糖アルコールと低吸湿性のオリゴ糖及び水溶性高分子と混合した水溶液とし、凍結乾燥を行うことにより、使用時まで安定に保つことができることを見出した。
【0010】
また、この皮膚外用剤組成物は、成形性、保形性に優れ、適度な固さを保ち輸送途上で割れ・カケ等が起こりにくく、吸湿等の影響による組成物の収縮及び、L−アスコルビン酸−2−リン酸塩の劣化がなく、安定性に優れ、使用時に容易に水等で溶解することができるといった特徴を有する。
【0011】
すなわち、本発明の皮膚外用剤組成物は、つぎの成分(a)〜(d)を配合した水溶液を混合し凍結乾燥して得られ、使用時に水又は化粧水等で溶解して使用することを特徴とする。
(a)L−アスコルビン酸−2−リン酸塩
(b)低吸湿性のオリゴ糖
(c)糖アルコール
(d)水溶性高分子
【0012】
本発明の皮膚外用剤組成物は、好ましくは上記成分中、(b)の低吸湿性のオリゴ糖がラフィノース、ラクトース、トレハロースから選ばれる一種又は二種以上であることを特徴とする。
【0013】
本発明の皮膚外用剤組成物は、好ましくは上記成分中、(c)の糖アルコールがマンニトールであることを特徴とする。
【0014】
本発明の皮膚外用剤組成物は、好ましくは上記成分中、(d)の水溶性高分子がヒドロキシエチルセルロース及び/又はヒアルロン酸ナトリウムであることを特徴とする。
【0015】
本発明の皮膚外用剤組成物は、好ましくは成分配合比が、(a)/(b+c)=1.0〜4.0(重量比)であり、かつ(b)/(c)=1.0〜4.0(重量比)であることを特徴とする。
【0016】
【発明の実施の形態】
以下、本発明の皮膚外用剤組成物に用いられる各成分について具体的に説明する。
【0017】
成分(a)のL−アスコルビン酸−2−リン酸塩としては、L−アスコルビン酸−2−リン酸ナトリウム、L−アスコルビン酸−2−リン酸マグネシウム、L−アスコルビン酸−2−リン酸カリウム、L−アスコルビン酸−2−リン酸カルシウム、L−アスコルビン酸−2−リン酸アンモニウム等が挙げられるが、これらに限定されるものではない。本発明においては、目的に応じて、これらL−アスコルビン酸−2−リン酸塩の一種又は二種以上を適宜組み合わせて用いることができる。この中でも、水溶性及び凍結乾燥後の性状形成の点からL−アスコルビン酸−2−リン酸のマグネシウム塩であるリン酸L−アスコルビルマグネシウム及び/又はナトリウム塩であるリン酸L−アスコルビルナトリウムが好ましい。
【0018】
L−アスコルビル酸−2−リン酸塩の配合量は凍結乾燥組成物全量中30.0〜90.0重量%が好ましく、さらに好ましくは50.0〜80.0重量%である。L−アスコルビン酸−2−リン酸塩の配合量がこの範囲であれば、固形物の成形性、保形性、溶解性において良好なものが得られる。
【0019】
成分(b)でいう低吸湿性のオリゴ糖とは、単糖や2種類以上の単糖が二個から十個結合した糖類の中で低吸湿性のものをいう。低吸湿性とは、40℃相対湿度75%の環境下に7日間放置し、その後重量の増加分を測定し、下記式により本発明で規定する吸湿度が3%以下のものをいう。具体的にはマルトース、ラクトース、セロビオース、メリビオース、スクロース、トレハロース、ラフィノース、α−シクロデキストリン等が挙げられるが、これらに限定されるものではない。これらの中でも吸湿度が0.1%以下のものが好ましく、具体的にはラクトース、トレハロース、ラフィノースが挙げられる。
吸湿度(%)=〔増加した重量(g)/サンプル重量(g)〕×100
【0020】
これら低吸湿性のオリゴ糖を用い凍結乾燥を行うと、吸湿性がほとんどないため、凍結乾燥後において空気中の水分を吸うことがほとんどない。このため、凍結乾燥後の経日安定性が向上する。
【0021】
成分(c)の糖アルコールとしては、四価の糖アルコールであるエリスリトール、五価の糖アルコールであるアラビトール、キシリトール、リビトール、六価の糖アルコールであるガラクチトール、グリシトール、マンニトール、七価の糖アルコールであるセドペヘプチトール、ベルセイトール、ボレミトール、糖アルコール無水物であるスチラシトール、ポリガリトール等が挙げられるが、これらに限定されるものではない。目的に応じてこれら糖アルコールの一種又は二種以上を適宜組み合わせて用いることができる。この中でも五価及び六価の糖アルコールが好ましく、さらには六価の糖アルコールであるマンニトールが最も好ましい。
【0022】
成分(a)L−アスコルビン酸−2−リン酸塩と、成分(b)低吸湿性のオリゴ糖と成分(c)の糖アルコールの合計配合量の配合比は(a)/(b+c)=1.0〜4.0(重量比)であることが好ましく、さらには2.0〜3.0(重量比)であることが好ましい。この範囲を超えて(a)を多く配合すると、固形物の成形がうまくいかず、逆に(b+c)の合計配合量を多くすると、凍結乾燥後の溶解性が低下してしまう。
【0023】
また、(b)と(c)の配合比は(b)/(c)=1.0〜4.0(重量比)であることが好ましく、さらには1.0〜2.0(重量比)であることが好ましい。この範囲より(b)が少なくなり、(c)が多くなると、凍結乾燥部の吸湿性が増加し溶解性が低下し、高温保存下において収縮が起こってしまう。また、逆にこの範囲より(b)が多くなり、(c)が少なくなると、凍結乾燥部の強度が低下し、輸送時等において割れ・カケといった現象が生じるといった耐衝撃性に問題が発生する。
【0024】
成分(d)の水溶性高分子は、特に制約はなく、その起源も、天然系、半合成系、合成系のいずれであっても良い。
【0025】
水溶性高分子としては、ローストビーンガム、グアーガム、クインシードガム、タラガム、カラギーナン、アルギン酸ナトリウム、ファーセレラン、アラビアガム、トラガカントガム、カラヤガム、ペクチン、澱粉、寒天、サンザンガム、プルラン、ヒアルロン酸ナトリウム、コラーゲン、カードラン、ジェランガム、キサンタンガム、ゼラチン、カゼイン、アルブミン、シェラック、キチン/キトサン、カルボキシビニルポリマー、コンドロイチン硫酸ナトリウム、ヒドロキシエチルセルロース、カルボキシメチルセルロース、カルボキシビニルポリマー、ポリビニルアルコール、ポリビニルピロリドン、ポリアクリル酸ナトリウム、アクリル酸メタクリル酸アルキル共重合体、メチルセルロース、ポリビニルピロリドン、ポリビニルメタアクリレート、ポリアクリル酸アミド、ポリアクリル酸ソーダ、マレイン酸共重合体、ポリビニルアルコール、ポリピニルピロリドン、ポリ酢酸ビニル、あるいはこれらの共重合体が挙げられるが、これらに限定されるものではない。また、これら水溶性高分子は、酸化、メチル化、カルボキシメチル化、ヒドロキシブチル化、ヒドロキシエチル化、りん酸化、カルボキシメチルヒドロキシエチル化、エチル化、カチオン化、水素添加、架橋などを施したものでも同様の効果を得ることができる。これら水溶性高分子は一種又は二種以上を適宜組み合せて用いることができる。
【0026】
これら水溶性高分子を凍結乾燥に用いた場合、水分を除去した後に皮膚外用剤組成物の内部に水溶性高分子物質が残存する。そして、これが粉体同士の結合剤の作用をするためと考えられ、固形物の保形性が向上する。
【0027】
この中でも、凍結乾燥後の保形性の点から、ヒドロキシエチルセルロース及び/又はヒアルロン酸ナトリウムが好ましい。
【0028】
本発明で用いられる水溶性高分子の配合量は凍結乾燥組成物全量中0.0001〜5.0重量%が好ましく、さらには0.001〜1.0重量%が好ましい。0.0001重量%未満では、凍結乾燥後の固形物の保形性が十分に得られず、また、5.0重量%を超えて配合すると、凍結乾燥後の固形物の溶解性が低下してしまう。
【0029】
本発明の固形皮膚外用剤組成物は、上記の成分(a)〜(d)を含有する混合水溶液を、凍結乾燥することによって得ることができる。より具体的には例えば以下のように製造される。
【0030】
成分(a)〜(d)を溶解し、凍結乾燥用の溶液を調節する。調整後の溶液を容器に一定量充填し、ゴム栓を半打栓して凍結乾燥機の棚上に並べる。その後、凍結乾燥機を稼働させて棚温を−30〜−40℃まで冷却し溶液を凍結し、真空ポンプにより乾燥庫を減圧して一次乾燥、ニ次乾燥を行う。乾燥時の棚温の設定は、−40〜35℃の範囲とし、そのときの乾燥庫内の真空度は0.01〜0.1Torrの範囲となるように調節する。乾燥の終了は、乾燥庫内の真空度の変化により確認する。乾燥終了後、容器内を窒素又は空気で置換して封栓を行い、乾燥庫より取り出す。
【0031】
本発明における皮膚外用剤組成物は、皮膚外用剤及び化粧料の基剤として他の成分と併用して使用することが好ましい。つまり水又はローション、化粧水等の水溶液に溶解させてから使用することが好ましい。
【0032】
本発明に使用できる成分としては本発明の効果を損わない質的、量的範囲で上記以外の任意の成分を配合することができ、化粧料に通常配合される成分、例えば、乳化剤、油性成分、界面活性剤、保湿剤、酸化防止剤、防腐剤、香料、各種ビタミン剤、着色剤、増粘剤、紫外線吸収剤、薬効成分、無機塩類等を配合することができる。
【0033】
(実施例)
以下に実施例及び比較例を挙げて本発明をより具体的に説明するが、本発明の技術的範囲が実施例によって何等限定されるものでないことはもちろんである。
【0034】
(製造方法)
表1及び表2に示す成分及び精製水を室温にて混合し、ガラス瓶に充填後、凍結乾燥し、製品を得た(表中組成は凍結後の組成を示す。)。配合量は重量%、配合比は重量比である。
【0035】
(評価項目)
得られた製品について、成形性、溶解性、高温安定性、耐衝撃性について評価した。評価は以下の基準で行った。得られた結果を表1、表2に併記する。
【0036】
成形性
凍結乾燥直後の形状、収縮の有無、ひび割れの有無を目視で確認し、凍結乾燥の成形性を評価した。
◎:均一に乾燥できており、収縮やひび割れがみられない。
○:均一に乾燥はできているが、収縮、ひび割れが僅かにみられる。もしくは僅かに乾燥にムラがみられるが、収縮、ひび割れはみられない。
△:僅かに乾燥にムラがみられ、収縮、ひび割れが僅かにみられる。
×:乾燥にムラがみられ、かなりの収縮、ひび割れがみられる。
【0037】
溶解性
凍結乾燥後の調合品に精製水を加え、そのときの溶解性を評価した。
◎:10秒以下で完全に溶解し、溶け残りもない。
○:溶解に10〜60秒を要するが、完全に溶解し、溶け残りもない。
△:溶解に60秒以上かかるが、完全に溶解し、溶け残りもない。
×:60秒以上振っても完全溶解せず、溶け残りがある。
【0038】
高温安定性
凍結乾燥後の調合品を50℃の高温槽で1ヶ月間保存したときの、形状の変化及び溶解性を評価した。
◎:ほとんど形状の変化がなく、溶解性も保存前とほぼ同等である。
○:若干の収縮がみられるが、溶解性は保存前とほぼ同等である。
△:若干の収縮がみられ、溶解性が保存前と比較してやや劣り、溶け残りが生じる。
×:大きな収縮がみられ、ほとんど溶解しない。
【0039】
耐衝撃性
ガラス瓶に充填された凍結乾燥品を上下に1分間振とうさせ、そのときの割れやカケを評価した。
◎:ほとんど割れ、カケはみられない。
○:一部にカケがみられる程度で、形状は保持されている。
△:全体にヒビが入り、やや大きなカケが生じる。
×:全体的に大きな割れが生じ、原型をとどめていない。
【0040】
【表1】

Figure 2004149468
【0041】
【表2】
Figure 2004149468
【0042】
実施例1、実施例2及び実施例3は、成分(a)、成分(b)、成分(c)及び成分(d)が好ましい量的範囲で配合されているので、成形性、溶解性、高温安定性、耐衝撃性のいずれにも優れた凍結乾燥品を得ることができ、L−アスコルビン酸−2−リン酸塩を含有しながら経日的な変臭・変色、べたつき感、刺激性のない安全性、使用性に優れた皮膚外用剤組成物を提供することができた。このようにしてなる皮膚外用剤組成物は、使用時に水又は化粧水等で溶解して使用される。
【0043】
比較例1は、成分(b)の低吸湿性のオリゴ糖が配合されていないので、溶解度、高温安定性に劣り、比較例2は、成分(c)の糖アルコールが配合されていないので、耐衝撃性に劣り、比較例3は、成分(d)の水溶性高分子が配合されていないので、成形性、高温安定性に劣り、比較例4、比較例5、比較例6及び比較例7は、成分(a)(b)(c)(d)のいずれもが配合されているが、成分(b)と(c)が好ましい量的限定の外にあるため、成形性、溶解性、高温安定性、耐衝撃性のいずれかの効果が減殺された。
【0044】
実施例4
以下に示す成分及び精製水を室温にて混合し、ガラス瓶に充填後、凍結乾燥し、製品を得た。
(表中組成は凍結後の組成を示す。)
L−アスコルビン酸−2−リン酸マグネシウム 75.0重量%
ラフィノース 12.5重量%
D−マンニトール 12.0重量%
ヒアルロン酸ナトリウム 0.1重量%
銅クロロフィリンナトリウム 0.05重量%
植物抽出物 0.35重量%
【0045】
実施例5
(1)〜(6)及び(10)の水相成分及び(7)〜(9)の油相成分をそれぞれ80℃に加熱溶解し均一化した後、油相を水相に添加しホモミキサーで乳化する。冷却後、凍結乾燥を行う。
(1)ショ糖モノステアリン酸エステル 4.0重量%
(2)L−アスコルビン酸−2−リン酸ナトリウム 8.0重量%
(3)D−マンニトール 2.0重量%
(4)ラクトース 3.0重量%
(5)ヒドロキシエチルセルロース 0.1重量%
(6)銅クロロフィリンナトリウム 0.0025重量%
(7)ミリスチン酸ミリスチル 5.0重量%
(8)ステアリン酸 12.0重量%
(9)オクチルドデカノール 2.0重量%
(10)精製水 残量
【0046】
実施例4及び実施例5で得られた凍結乾燥品は成形性、溶解性、高温安定性、耐衝撃性に優れたものであり、L−アスコルビン酸−2−リン酸塩を含有しながら経日的な変臭・変色、べたつき感、刺激性のない、安全性、使用性に優れた皮膚外用剤を提供することができた。
【0047】
【発明の効果】
本発明は、上述のように、使用時に水又は化粧水等で溶解する皮膚外用剤組成物において、
(a)L−アスコルビン酸−2−リン酸塩
(b)低吸湿性のオリゴ糖
(c)糖アルコール
(d)水溶性高分子
を配合した水溶液を混合し、凍結乾燥することで、成形性、溶解性、高温安定性、耐衝撃性に優れた凍結乾燥品を得ることができ、L−アスコルビン酸−2−リン酸塩を含有しながら経日的な変臭・変色、べたつき感、刺激性のない安全性、使用性に優れた皮膚外用剤組成物を提供することができる。[0001]
TECHNICAL FIELD OF THE INVENTION
The present invention relates to an external preparation for skin that can stably maintain L-ascorbic acid-2-phosphate, which is an unstable water-soluble ascorbic acid derivative in the presence of water.
[0002]
[Prior art]
L-ascorbic acid-2-phosphate is recognized for its high usefulness such as suppression of melanin production, antioxidant properties, radical scavenging ability, and promotion of collagen synthesis. It has been incorporated into various skin external preparation compositions for various purposes such as preventing wrinkles and moisturizing the skin.
[0003]
L-ascorbic acid-2-phosphate is susceptible to oxidation, pH change, microorganisms and the like in the presence of water, and as a result, L-ascorbic acid-2-phosphate is decomposed. Are generated, thereby causing problems such as yellowing of the appearance of the system and accompanied by unpleasant odor. The state of the system is kept constant until use, and L-ascorbic acid-2-phosphate is produced. At present, it was difficult to maintain stability.
[0004]
In order to solve such a problem, a contrivance has conventionally been made to stabilize L-ascorbic acid-2-phosphate by blending a stabilizer such as a sequestering agent, a preservative, and a pH adjuster. Was.
[0005]
However, in the above-mentioned solutions, satisfactory results cannot be obtained, especially in terms of discoloration and odor, and it is necessary to greatly increase the amount of a stabilizer in order to maintain stability. The burden is large and the usability is inferior, and improvements have been required.
[0006]
On the other hand, as a method that can be improved without increasing the amount of the stabilizer, there is a method of freeze-drying L-ascorbic acid-2-phosphate (Japanese Patent Laid-Open No. 10-130124). However, since L-ascorbic acid-2-phosphate has a very high hygroscopicity, it often contains moisture in the air after freeze-drying, often causing discoloration, odor and deterioration in solubility. In some cases, freeze-drying at a relatively high blending amount is difficult in production due to high hygroscopicity. Furthermore, in order to prevent these phenomena, a method of adding a sugar alcohol is used. However, since the sugar alcohol itself has a hygroscopic property, it is not sufficient to freeze-dry L-ascorbic acid-2-phosphate. Was not.
[0007]
In addition, when freeze-drying is performed using only low-hygroscopic oligosaccharides (Japanese Patent Application Laid-Open No. 2002-000248), there is a disadvantage that the freeze-dried product is severely shrunk, brittle and easily cracked or chipped, which greatly impairs the commercial value. was there.
[0008]
[Problems to be solved by the invention]
The present invention solves the problem that L-ascorbic acid-2-phosphate, which is a water-soluble ascorbic acid derivative, is unstable in the coexistence with water, and is excellent in moldability and shape retention, and suitable. It maintains its hardness and is not easily cracked or chipped during transportation, does not deteriorate or shrink L-ascorbic acid-2-phosphate due to the effects of moisture absorption, etc., has excellent stability, and is easily dissolved in water when used. An object of the present invention is to provide a skin external preparation composition that can be used.
[0009]
[Means for Solving the Problems]
The present inventors have conducted intensive studies on the external composition for skin to solve the above problems, and as a result, found that L-ascorbic acid-2-phosphorus, which is a water-soluble ascorbic acid derivative that is unstable in the presence of water. The present inventors have found that an aqueous solution obtained by mixing an acid salt with a sugar alcohol, a low-hygroscopic oligosaccharide and a water-soluble polymer, and freeze-drying the aqueous acid salt can stably maintain it until use.
[0010]
In addition, the composition for external use on skin has excellent moldability and shape retention properties, maintains appropriate hardness, hardly causes cracks and chips during transportation, shrinks the composition due to the influence of moisture absorption and the like, and reduces L-ascorbin. The acid-2-phosphate is characterized in that it is not deteriorated, has excellent stability, and can be easily dissolved with water or the like at the time of use.
[0011]
That is, the skin external preparation composition of the present invention is obtained by mixing and freeze-drying an aqueous solution containing the following components (a) to (d), and dissolving with water or lotion at the time of use. It is characterized by.
(A) L-ascorbic acid-2-phosphate (b) low hygroscopic oligosaccharide (c) sugar alcohol (d) water-soluble polymer
The skin external preparation composition of the present invention is preferably characterized in that, in the above components, the low-hygroscopic oligosaccharide (b) is one or more selected from raffinose, lactose and trehalose.
[0013]
The skin external preparation composition of the present invention is preferably characterized in that, in the above-mentioned components, the sugar alcohol of (c) is mannitol.
[0014]
The skin external preparation composition of the present invention is preferably characterized in that, in the above-mentioned components, the water-soluble polymer (d) is hydroxyethyl cellulose and / or sodium hyaluronate.
[0015]
In the skin external preparation composition of the present invention, the component mixing ratio is preferably (a) / (b + c) = 1.0 to 4.0 (weight ratio), and (b) / (c) = 1. 0 to 4.0 (weight ratio).
[0016]
BEST MODE FOR CARRYING OUT THE INVENTION
Hereinafter, each component used in the skin external preparation composition of the present invention will be specifically described.
[0017]
The L-ascorbic acid-2-phosphate of component (a) includes L-ascorbic acid-2-sodium phosphate, L-ascorbic acid-2-magnesium phosphate, and L-ascorbic acid-2-potassium phosphate , L-ascorbic acid-2-calcium phosphate, L-ascorbic acid-2-ammonium phosphate and the like, but are not limited thereto. In the present invention, one or a combination of two or more of these L-ascorbic acid-2-phosphates can be used according to the purpose. Among them, L-ascorbyl magnesium phosphate, which is a magnesium salt of L-ascorbic acid-2-phosphate, and / or sodium L-ascorbyl phosphate, which is a sodium salt, are preferable from the viewpoint of water solubility and property formation after freeze-drying. .
[0018]
The compounding amount of L-ascorbic acid-2-phosphate is preferably 30.0 to 90.0% by weight, more preferably 50.0 to 80.0% by weight, based on the whole amount of the freeze-dried composition. When the compounding amount of L-ascorbic acid-2-phosphate is in this range, a solid having good moldability, shape retention and solubility can be obtained.
[0019]
The oligosaccharide with low hygroscopicity referred to as the component (b) is a monosaccharide or a saccharide in which two or more monosaccharides are bonded to two to ten monosaccharides, and has low hygroscopicity. The term "low hygroscopicity" means that the film is left in an environment of 40 ° C. and a relative humidity of 75% for 7 days, and then the weight increase is measured. Specific examples include, but are not limited to, maltose, lactose, cellobiose, melibiose, sucrose, trehalose, raffinose, α-cyclodextrin and the like. Among these, those having a moisture absorption of 0.1% or less are preferable, and specific examples include lactose, trehalose, and raffinose.
Moisture absorption (%) = [increased weight (g) / sample weight (g)] × 100
[0020]
When freeze-drying is performed using these low-hygroscopic oligosaccharides, there is almost no hygroscopicity, and therefore, there is almost no absorption of moisture in the air after freeze-drying. Therefore, the stability over time after freeze-drying is improved.
[0021]
Examples of the sugar alcohol of component (c) include erythritol, which is a tetravalent sugar alcohol, arabitol, which is a pentavalent sugar alcohol, xylitol, ribitol, galactitol which is a hexavalent sugar alcohol, glycitol, mannitol, and heptavalent sugar Examples include, but are not limited to, alcohols such as sedopeheptitol, versaceitol, bolemitol, and sugar alcohol anhydrides such as stylactitol and polygalitol. One or more of these sugar alcohols can be used in an appropriate combination depending on the purpose. Of these, pentavalent and hexavalent sugar alcohols are preferred, and mannitol, which is a hexavalent sugar alcohol, is most preferred.
[0022]
The compounding ratio of the total amount of component (a) L-ascorbic acid-2-phosphate, component (b) low-hygroscopic oligosaccharide and component (c) sugar alcohol is (a) / (b + c) = It is preferably from 1.0 to 4.0 (weight ratio), and more preferably from 2.0 to 3.0 (weight ratio). If the amount of (a) is more than this range, the molding of the solid material will not be successful, and if the total amount of (b + c) is increased, the solubility after freeze-drying will decrease.
[0023]
Further, the compounding ratio of (b) and (c) is preferably (b) / (c) = 1.0 to 4.0 (weight ratio), and more preferably 1.0 to 2.0 (weight ratio). ) Is preferable. If (b) is smaller and (c) is larger than this range, the hygroscopicity of the freeze-dried portion increases, the solubility decreases, and shrinkage occurs during high-temperature storage. Conversely, when (b) is larger than this range and (c) is smaller, the strength of the freeze-dried portion is reduced, and a problem such as cracking or chipping occurs during transportation or the like, causing a problem in impact resistance. .
[0024]
The water-soluble polymer of the component (d) is not particularly limited, and its origin may be any of a natural system, a semi-synthetic system, and a synthetic system.
[0025]
Examples of the water-soluble polymer include roast bean gum, guar gum, quinceed gum, tara gum, carrageenan, sodium alginate, furceleran, gum arabic, tragacanth gum, karaya gum, pectin, starch, agar, sanzan gum, pullulan, sodium hyaluronate, collagen, card Orchid, gellan gum, xanthan gum, gelatin, casein, albumin, shellac, chitin / chitosan, carboxyvinyl polymer, sodium chondroitin sulfate, hydroxyethylcellulose, carboxymethylcellulose, carboxyvinyl polymer, polyvinyl alcohol, polyvinylpyrrolidone, sodium polyacrylate, methacryl acrylate Acid alkyl copolymer, methyl cellulose, polyvinyl pyrrolidone, polyvinyl meta Acrylate, polyacrylic acid amide, sodium polyacrylate, maleate copolymers, polyvinyl alcohol, poly pin alkenyl pyrrolidone, polyvinyl acetate, or is a copolymer thereof, but the invention is not limited thereto. These water-soluble polymers have been subjected to oxidation, methylation, carboxymethylation, hydroxybutylation, hydroxyethylation, phosphorylation, carboxymethylhydroxyethylation, ethylation, cationization, hydrogenation, crosslinking, etc. However, the same effect can be obtained. These water-soluble polymers can be used alone or in appropriate combination of two or more kinds.
[0026]
When these water-soluble polymers are used for freeze-drying, the water-soluble polymer substance remains inside the skin external preparation composition after removing water. Then, it is considered that this acts as a binder between the powders, and the shape retention of the solid is improved.
[0027]
Among these, hydroxyethyl cellulose and / or sodium hyaluronate are preferred from the viewpoint of shape retention after freeze-drying.
[0028]
The amount of the water-soluble polymer used in the present invention is preferably 0.0001 to 5.0% by weight, more preferably 0.001 to 1.0% by weight, based on the whole amount of the freeze-dried composition. If the amount is less than 0.0001% by weight, the shape retention of the solid after lyophilization cannot be sufficiently obtained. If the amount exceeds 5.0% by weight, the solubility of the solid after lyophilization decreases. Would.
[0029]
The solid skin external preparation composition of the present invention can be obtained by freeze-drying a mixed aqueous solution containing the above components (a) to (d). More specifically, for example, it is manufactured as follows.
[0030]
Dissolve components (a)-(d) and prepare a solution for lyophilization. A predetermined amount of the adjusted solution is filled in a container, and a rubber stopper is half-stoppered and arranged on a shelf of a freeze dryer. Thereafter, the freeze dryer is operated to cool the shelf temperature to -30 to -40 ° C to freeze the solution, and the drying cabinet is depressurized by a vacuum pump to perform primary drying and secondary drying. The shelf temperature during drying is set in the range of -40 to 35 ° C, and the degree of vacuum in the drying cabinet at that time is adjusted to be in the range of 0.01 to 0.1 Torr. The end of the drying is confirmed by a change in the degree of vacuum in the drying cabinet. After the drying is completed, the inside of the container is replaced with nitrogen or air, and the container is sealed.
[0031]
The external preparation composition for skin in the present invention is preferably used in combination with other components as a base for external preparation for skin and cosmetics. That is, it is preferable to use it after dissolving it in water or an aqueous solution such as a lotion or lotion.
[0032]
As the components that can be used in the present invention, any components other than the above can be blended in a qualitative and quantitative range that does not impair the effects of the present invention, and components usually blended in cosmetics, for example, emulsifiers, oils Components, surfactants, humectants, antioxidants, preservatives, fragrances, various vitamins, coloring agents, thickeners, ultraviolet absorbers, medicinal ingredients, inorganic salts, and the like can be added.
[0033]
(Example)
Hereinafter, the present invention will be described more specifically with reference to Examples and Comparative Examples. However, it is needless to say that the technical scope of the present invention is not limited by the Examples.
[0034]
(Production method)
The components shown in Tables 1 and 2 and purified water were mixed at room temperature, filled in a glass bottle, and freeze-dried to obtain a product (the composition in the table indicates the composition after freezing). The compounding amount is% by weight and the compounding ratio is by weight.
[0035]
(Evaluation item)
The obtained product was evaluated for moldability, solubility, high-temperature stability, and impact resistance. The evaluation was performed according to the following criteria. The results obtained are shown in Tables 1 and 2.
[0036]
Formability Immediately after freeze-drying, the shape, the presence or absence of shrinkage, and the presence or absence of cracks were visually confirmed, and the freeze-dryability was evaluated.
:: Uniformly dried, no shrinkage or cracking observed.
:: Evenly dried, but shrinkage and cracks are slightly observed. Alternatively, drying is slightly uneven, but no shrinkage or cracking is observed.
Δ: Slight unevenness in drying, shrinkage and cracks slightly observed.
×: Unevenness is observed in drying, and considerable shrinkage and cracking are observed.
[0037]
Purified water was added to the freeze-dried preparation, and the solubility at that time was evaluated.
◎: Completely dissolved within 10 seconds or less, with no remaining undissolved.
:: It takes 10 to 60 seconds to dissolve, but it is completely dissolved and there is no undissolved residue.
Δ: It takes 60 seconds or more to dissolve, but completely dissolves, and there is no undissolved residue.
X: Even if shaken for 60 seconds or more, it does not completely dissolve and there is undissolved residue.
[0038]
High Temperature Stability The freeze-dried preparation was evaluated for shape change and solubility when stored in a 50 ° C. high temperature bath for one month.
A: Almost no change in shape, and solubility is almost the same as before storage.
:: Some shrinkage is observed, but the solubility is almost the same as before storage.
Δ: Slight shrinkage was observed, the solubility was slightly inferior to that before storage, and undissolved residue occurred.
X: Large shrinkage is observed and hardly dissolves.
[0039]
The freeze-dried product filled in the impact-resistant glass bottle was shaken up and down for 1 minute, and cracks and chips at that time were evaluated.
A: Almost no cracking and no chipping.
:: The shape is maintained to the extent that the chip is partially observed.
Δ: Cracks are formed on the whole, and a somewhat large chip is generated.
X: A large crack was generated as a whole, and the prototype was not stopped.
[0040]
[Table 1]
Figure 2004149468
[0041]
[Table 2]
Figure 2004149468
[0042]
In Example 1, Example 2 and Example 3, the components (a), (b), (c) and (d) are blended in a preferable quantitative range, so that moldability, solubility, A freeze-dried product excellent in both high-temperature stability and impact resistance can be obtained, and daily odor and discoloration, stickiness, and irritation while containing L-ascorbic acid-2-phosphate. Thus, it was possible to provide a skin external preparation composition having excellent safety and ease of use. The skin external preparation composition thus obtained is used by dissolving it with water or lotion at the time of use.
[0043]
Comparative Example 1 was inferior in solubility and high-temperature stability because the low-hygroscopic oligosaccharide of component (b) was not blended. Comparative Example 2 was not blended with the sugar alcohol of component (c). Inferior in impact resistance, Comparative Example 3 was inferior in moldability and high-temperature stability because the water-soluble polymer of component (d) was not added, and was inferior in Comparative Example 4, Comparative Example 5, Comparative Example 6, and Comparative Example No. 7 contains all of the components (a), (b), (c) and (d), but since the components (b) and (c) are out of the preferable quantitative limits, the moldability and the solubility are high. Any of the effects of high temperature stability and impact resistance were diminished.
[0044]
Example 4
The following components and purified water were mixed at room temperature, filled in a glass bottle, and then lyophilized to obtain a product.
(The composition in the table indicates the composition after freezing.)
L-ascorbic acid-2-magnesium phosphate 75.0% by weight
Raffinose 12.5% by weight
D-mannitol 12.0% by weight
Sodium hyaluronate 0.1% by weight
Copper chlorophyllin sodium 0.05% by weight
0.35% by weight of plant extract
[0045]
Example 5
After the aqueous phase components (1) to (6) and (10) and the oil phase components (7) to (9) are each heated to 80 ° C. and homogenized, the oil phase is added to the aqueous phase, and a homomixer is added. Emulsify with After cooling, freeze drying is performed.
(1) Sucrose monostearate 4.0% by weight
(2) L-ascorbic acid-2-sodium phosphate 8.0% by weight
(3) D-mannitol 2.0% by weight
(4) Lactose 3.0% by weight
(5) 0.1% by weight of hydroxyethyl cellulose
(6) Copper chlorophyllin sodium 0.0025% by weight
(7) Myristyl myristate 5.0% by weight
(8) Stearic acid 12.0% by weight
(9) Octyldodecanol 2.0% by weight
(10) Remaining amount of purified water
The freeze-dried products obtained in Examples 4 and 5 are excellent in moldability, solubility, high-temperature stability, and impact resistance, and contain L-ascorbic acid-2-phosphate. A skin external preparation excellent in safety and usability without daily odor / discoloration, sticky feeling, irritation, could be provided.
[0047]
【The invention's effect】
The present invention is, as described above, a skin external preparation composition that dissolves in water or lotion when used,
(A) L-ascorbic acid-2-phosphate (b) Low moisture-absorbing oligosaccharide (c) Sugar alcohol (d) An aqueous solution containing a water-soluble polymer is mixed and freeze-dried to form a mold. A freeze-dried product having excellent solubility, high-temperature stability, and impact resistance can be obtained, and it contains daily L-ascorbic acid-2-phosphate, and has daily odor and discoloration, stickiness, and irritation. It is possible to provide a skin external preparation composition which is excellent in safety and usability.

Claims (5)

つぎの成分(a)〜(d)を配合した水溶液を混合し凍結乾燥して得られ、使用時に水又は化粧水等で溶解して使用することを特徴とする皮膚外用剤組成物。
(a)L−アスコルビン酸−2−リン酸塩
(b)低吸湿性のオリゴ糖
(c)糖アルコール
(d)水溶性高分子
A skin external preparation composition obtained by mixing and freeze-drying an aqueous solution containing the following components (a) to (d), and dissolving with water or a lotion at the time of use.
(A) L-ascorbic acid-2-phosphate (b) low hygroscopic oligosaccharide (c) sugar alcohol (d) water-soluble polymer
成分(b)の低吸湿性のオリゴ糖がラフィノース、ラクトース、トレハロースから選ばれる一種又は二種以上である請求項1に記載の皮膚外用剤組成物。The skin external preparation composition according to claim 1, wherein the oligosaccharide having low hygroscopicity of the component (b) is one or more selected from raffinose, lactose, and trehalose. 成分(c)の糖アルコールがマンニトールである請求項1又は請求項2に記載の皮膚外用剤組成物。The skin external preparation composition according to claim 1 or 2, wherein the sugar alcohol of the component (c) is mannitol. 成分(d)の水溶性高分子がヒドロキシエチルセルロース及び/又はヒアルロン酸ナトリウムである請求項1、請求項2又は請求項3に記載の皮膚外用剤組成物。The composition for external use on skin according to claim 1, 2 or 3, wherein the water-soluble polymer of the component (d) is hydroxyethyl cellulose and / or sodium hyaluronate. 成分配合比が、(a)/(b+c)=1.0〜4.0(重量比)であり、かつ(b)/(c)=1.0〜4.0(重量比)である請求項1、請求項2、請求項3又は請求項4に記載の皮膚外用剤組成物。Claims wherein the component compounding ratio is (a) / (b + c) = 1.0-4.0 (weight ratio) and (b) / (c) = 1.0-4.0 (weight ratio). The external preparation composition for skin according to claim 1, 2, 3, or 4.
JP2002317621A 2002-10-31 2002-10-31 Skin preparation for external use Expired - Fee Related JP4377123B2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2002317621A JP4377123B2 (en) 2002-10-31 2002-10-31 Skin preparation for external use

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP2002317621A JP4377123B2 (en) 2002-10-31 2002-10-31 Skin preparation for external use

Publications (2)

Publication Number Publication Date
JP2004149468A true JP2004149468A (en) 2004-05-27
JP4377123B2 JP4377123B2 (en) 2009-12-02

Family

ID=32460969

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2002317621A Expired - Fee Related JP4377123B2 (en) 2002-10-31 2002-10-31 Skin preparation for external use

Country Status (1)

Country Link
JP (1) JP4377123B2 (en)

Cited By (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2008106035A (en) * 2006-09-29 2008-05-08 Fancl Corp Freeze-dried preparation of l-ascorbic acid-2-phosphoric acid-6-fatty acid and cosmetic
EP2243470A1 (en) 2009-04-22 2010-10-27 Dr. Suwelack Skin & Health Care AG Freeze-dried coated moulded body
EP2243469A1 (en) 2009-04-22 2010-10-27 Dr. Suwelack Skin & Health Care AG Freeze-dried form body containing magnesium ascorbyl phosphate
EP2243472A1 (en) 2009-04-22 2010-10-27 Dr. Suwelack Skin & Health Care AG Freeze-dried agent compound
JP6404405B1 (en) * 2017-06-14 2018-10-10 株式会社 資生堂 Tablet-type freeze-dried cosmetics
WO2018235147A1 (en) 2017-06-19 2018-12-27 株式会社 資生堂 Tablet-type freeze-dried cosmetic
CN114681349A (en) * 2022-05-16 2022-07-01 珠海市医健生物技术研发中心 Composition for changing skin darkness and brightening skin and preparation method thereof

Cited By (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2008106035A (en) * 2006-09-29 2008-05-08 Fancl Corp Freeze-dried preparation of l-ascorbic acid-2-phosphoric acid-6-fatty acid and cosmetic
JP4495748B2 (en) * 2006-09-29 2010-07-07 株式会社ファンケル L-ascorbic acid-2-phosphate-6-fatty acid lyophilized preparation and cosmetics
EP2243470A1 (en) 2009-04-22 2010-10-27 Dr. Suwelack Skin & Health Care AG Freeze-dried coated moulded body
EP2243469A1 (en) 2009-04-22 2010-10-27 Dr. Suwelack Skin & Health Care AG Freeze-dried form body containing magnesium ascorbyl phosphate
EP2243472A1 (en) 2009-04-22 2010-10-27 Dr. Suwelack Skin & Health Care AG Freeze-dried agent compound
JP2010254689A (en) * 2009-04-22 2010-11-11 Dr Suwelack Skin & Health Care Ag Freeze-dried molded article containing magnesium ascorbyl phosphate
EP3199147A1 (en) 2009-04-22 2017-08-02 MedSkin Solutions Dr. Suwelack AG Freeze-dried agent compound
JP6404405B1 (en) * 2017-06-14 2018-10-10 株式会社 資生堂 Tablet-type freeze-dried cosmetics
JP2019001745A (en) * 2017-06-14 2019-01-10 株式会社 資生堂 Tablet lyophilized cosmetic
WO2018235147A1 (en) 2017-06-19 2018-12-27 株式会社 資生堂 Tablet-type freeze-dried cosmetic
KR20200016878A (en) 2017-06-19 2020-02-17 가부시키가이샤 시세이도 Tablet Freeze Dried Cosmetic
CN114681349A (en) * 2022-05-16 2022-07-01 珠海市医健生物技术研发中心 Composition for changing skin darkness and brightening skin and preparation method thereof

Also Published As

Publication number Publication date
JP4377123B2 (en) 2009-12-02

Similar Documents

Publication Publication Date Title
ES2639130T3 (en) Pharmaceutical formulation for the manufacture of rapidly disintegrating tablets
KR930010623B1 (en) Process for preparing stable freeze-dried preparations of an anticancer platinum complex
EP3017808B1 (en) Water-soluble hyaluronic acid gel and method for producing same
JP2865320B2 (en) Solid cosmetic composition
CA2380068A1 (en) Pullulan film compositions
TW200608975A (en) Pharmaceutical compositions
JP2009196987A (en) Tooth paste composition for periodontal disease
WO2002005855A1 (en) Pharmaceutical compositions containing dds compounds
JPH07291854A (en) Medicinal preparation improved in solubility
EP2552420B1 (en) Suspension and cake composition containing carbostyryl derivative and silicone oil and/or silicone oil derivative
WO2008010403A1 (en) Method for preventing coloration of catechins and dentifrice composition
JP4377123B2 (en) Skin preparation for external use
EP3049158B1 (en) Oral care composition
JP2006182750A (en) Freeze-dried cosmetic and method for producing the same
EP2258368A3 (en) Pharmaceutical compositions for nasal delivery
WO2017104759A1 (en) Tablet-type freeze-dried cosmetic
WO2018235147A1 (en) Tablet-type freeze-dried cosmetic
KR20180006068A (en) Disposable lightweight freeze-dried cosmetics
JP2019530645A (en) Solid pharmaceutical composition comprising amorphous sofosbuvir
EP3777825A1 (en) Composition of freeze-dried formulation, cosmetic kit for external use on skin including the same, and its use
JP2008024652A (en) Dentifrice composition
JP2009196986A (en) Dentifrice composition
JP2016132664A (en) L-ascorbic acid-compounding lyophilization cosmetics
KR20180114881A (en) Disposable lightweight freeze-dried cosmetics
JP2010105965A (en) Vancomycin preparation

Legal Events

Date Code Title Description
A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20041111

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20041207

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20050128

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20051206

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20060105

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20060106

A911 Transfer to examiner for re-examination before appeal (zenchi)

Free format text: JAPANESE INTERMEDIATE CODE: A911

Effective date: 20060210

A912 Re-examination (zenchi) completed and case transferred to appeal board

Free format text: JAPANESE INTERMEDIATE CODE: A912

Effective date: 20070209

A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20090910

R150 Certificate of patent or registration of utility model

Ref document number: 4377123

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

Free format text: JAPANESE INTERMEDIATE CODE: R150

FPAY Renewal fee payment (event date is renewal date of database)

Free format text: PAYMENT UNTIL: 20120918

Year of fee payment: 3

FPAY Renewal fee payment (event date is renewal date of database)

Free format text: PAYMENT UNTIL: 20150918

Year of fee payment: 6

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

LAPS Cancellation because of no payment of annual fees